Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Hards 2018 Proc Natl Acad Sci U S A

From Bioblast
Publications in the MiPMap
Hards K, McMillan DGG, Schurig-Briccio LA, Gennis RB, Lill H, Bald D, Cook GM (2018) Ionophoric effects of the antitubercular drug bedaquiline. Proc Natl Acad Sci U S A 115:7326-31.

Β» PMID: 29941569

Hards K, McMillan DGG, Schurig-Briccio LA, Gennis RB, Lill H, Bald D, Cook GM (2018) Proc Natl Acad Sci U S A

Abstract: Bedaquiline (BDQ), an inhibitor of the mycobacterial F1Fo-ATP synthase, has revolutionized the antitubercular drug discovery program by defining energy metabolism as a potent new target space. Several studies have recently suggested that BDQ ultimately causes mycobacterial cell death through a phenomenon known as uncoupling. The biochemical basis underlying this, in BDQ, is unresolved and may represent a new pathway to the development of effective therapeutics. In this communication, we demonstrate that BDQ can inhibit ATP synthesis in Escherichia coli by functioning as a H+/K+ ionophore, causing transmembrane pH and potassium gradients to be equilibrated. Despite the apparent lack of a BDQ-binding site, incorporating the E. coli Fo subunit into liposomes enhanced the ionophoric activity of BDQ. We discuss the possibility that localization of BDQ at F1Fo-ATP synthases enables BDQ to create an uncoupled microenvironment, by antiporting H+/K+ Ionophoric properties may be desirable in high-affinity antimicrobials targeting integral membrane proteins. β€’ Keywords: Bedaquiline, Ionophore, Respiration, Tuberculosis, Uncoupler β€’ Bioblast editor: Plangger M, Kandolf G


Labels: MiParea: Respiration, Pharmacology;toxicology  Pathology: Other 

Organism: Eubacteria 

Preparation: Intact organism 

Regulation: ATP production, Ion;substrate transport, Uncoupler 


HRR: O2k-Fluorometer 

Labels, 2018-08